Modeyso (Dordaviprone)

Dordaviprone is a medicine used to treat a rare brain tumor called diffuse midline glioma with an H3 K27M change, after other treatment has stopped working. It is taken as a capsule by mouth. It works by switching on a stress process inside the tumor cells that helps kill them.

Brand names:Modeyso
Medication

What people taking Modeyso (Dordaviprone) report

Every report comes from a Lived member, sent anonymously.

Have you tried Modeyso (Dordaviprone) for DIPG Brain Tumors?

NameHow it went

About Modeyso (Dordaviprone)

What It's For

Dordaviprone, sold as Modeyso, is a prescription cancer medicine for diffuse midline glioma, a rare and aggressive brain tumor that grows in structures along the center of the brain, such as the thalamus. It is approved for adults and children 1 year and older whose tumor carries a specific genetic change called an H3 K27M mutation, and only after the tumor has grown despite earlier treatment, which is usually radiation. Because these tumors grow into vital areas of the brain, surgery usually cannot remove them, and radiation is the standard first treatment. The approval is an accelerated approval: the FDA granted it because the drug shrank tumors in some patients and those responses lasted months, but it has not yet been shown to help people live longer. Continued approval depends on a confirmatory trial. The tumor tissue has to be tested for the H3 K27M mutation before treatment. There is not yet an FDA-approved test for it, so the care team relies on the pathology lab's testing of the biopsy.

How It Works

Dordaviprone is a small molecule that crosses into the brain and acts on the tumor cells' energy machinery. It switches on ClpP, an enzyme inside mitochondria (the structures that produce a cell's energy), and it also blocks the dopamine D2 receptor. Together these effects push the tumor cells into a stress state that can lead them to die. In laboratory models, the drug also partly reversed the chemical change that the H3 K27M mutation causes in the tumor cells' DNA packaging. That is why it is aimed at tumors with this mutation. These findings come from laboratory studies, and they do not predict who will respond.

Dosage & Administration

Dordaviprone comes as 125 mg capsules taken by mouth once a week, on the same day each week. The adult dose is 625 mg (five capsules taken together), and children's doses are based on body weight. It is taken on an empty stomach, at least 1 hour before or 3 hours after eating. Capsules are swallowed whole. For a child or anyone who cannot swallow capsules, they can be opened and the contents mixed with a small amount of water, apple juice, lemonade or a sports drink, following the Instructions for Use that come with the medicine. If a dose is missed by 2 days or less, take it when remembered; if more than 2 days have passed, skip it and take the next dose on the usual day. If vomiting happens after a dose, do not take another one that week. Treatment continues as long as the tumor is controlled and side effects are manageable, and the care team may pause or lower the dose if side effects become significant.

Side Effects

The most common side effects are tiredness, headache, nausea, vomiting, and muscle, joint or bone pain. Blood tests often show changes such as lower white blood cell counts, lower calcium and higher liver enzymes, which is why bloodwork is part of follow-up. In the studies, people also had weakness on one side of the body, unsteady walking, slurred speech, trouble swallowing and problems with the nerves that control the face and eyes. These overlap with the symptoms the tumor itself causes, so any new or worsening neurological symptom should be reported to the care team promptly rather than assumed to be a side effect. Seizures and blood clots were less common. Two reactions need emergency help right away. Signs of a severe allergic reaction include swelling of the face or throat, wheezing or trouble breathing, or feeling faint, especially with hives or rash. Signs of a dangerous heart rhythm include feeling lightheaded or faint, a fast or pounding heartbeat, or sudden shortness of breath.

Interactions & Warnings

Dordaviprone can lengthen the QT interval, the part of the heartbeat when the heart's electrical system resets. A longer QT interval raises the risk of a dangerous irregular rhythm. The care team checks an ECG (electrocardiogram, a tracing of the heart's electrical activity) and blood salts (electrolytes) before treatment and as needed afterward, and checks more often in people with heart failure, long QT syndrome or other rhythm problems. Other medicines that also lengthen the QT interval are avoided where possible. The liver breaks down dordaviprone mainly through an enzyme called CYP3A4. Medicines that block this enzyme, including some antifungals such as itraconazole and fluconazole and some antibiotics such as erythromycin, can raise dordaviprone levels and the risk of side effects. Medicines that speed it up, such as the tuberculosis antibiotic rifampin, can lower levels enough to weaken the drug's effect. Because many interactions are possible, check with the care team or pharmacist before starting or stopping any medicine or supplement. Dordaviprone can harm a developing baby. A pregnancy test is done before starting in anyone who could become pregnant. Effective birth control is needed during treatment and for 1 month after the last dose, both for people who could become pregnant and for male patients whose partners could. Tell the care team right away about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for 1 week after the last dose. The medicine may also affect fertility in both sexes.

What to Expect

Treatment involves regular visits, bloodwork, ECGs and periodic brain scans to see whether the tumor is shrinking, stable or growing. In the studies that led to approval, about 1 in 5 people had a measurable shrinkage of their tumor. For those who responded, it took a median of about 3.6 months to see it on scans, and the response lasted a median of about 10 months. Many people do not have a response, and it is not yet known how much the drug extends life. The evidence comes from a small group of 50 carefully selected patients across several studies without a comparison group. Those studies did not include people with tumors in the pons (often called DIPG), tumors in the spinal cord or tumors that had spread into the spinal fluid, so the expected benefit for those groups is less clear. Because it is a weekly pill, the routine is lighter than daily treatment, and the care team weighs ongoing side effects against tumor control at each check-in.

Questions to Ask Your Doctor

  1. 1.How was the H3 K27M mutation confirmed in my tumor (or my child's), and does the tumor's location fit the people this drug was studied in?
  2. 2.How will we know whether dordaviprone is working, and how often will scans, ECGs and blood tests be done?
  3. 3.Do any of my current medicines or supplements interact with dordaviprone or affect my heart rhythm?
  4. 4.Which new symptoms should I report to you, and how will we tell a side effect from tumor progression?
  5. 5.Are there clinical trials or other treatments I should consider alongside or instead of this one?

Last reviewed • Oct 2026

Educational content, not medical advice.